|
Draft Guidance Suggests Updated Tool for Assessing Suicidal Thoughts, Behavior in Trials
Drugmakers should use an updated instrument for the prospective assessment of suicidal thoughts and behaviors during clinical trials and follow new FDA advice on which trials and patients need such assessments, according to a new draft guidance.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives